Background insights

Financials

Lupin Limited

Lupin of the future

• Infrastructure in place to meet the future challenges
• Professionalization of Mgmt by inducting top notch senior professionals
• Continue strong QA program
• Leveraging R&D strengths for business
• Leverage IT initiatives for business
• Maximize value for all stakeholders
• High degree of focus on Corporate Governance

AMIT MAKHOLIA 2K15GA013

ANAMIKA GUPTA 2K15GA014

ANJU SIVAN 2K15GA016

ANKIT BEHL 2K15GA017

Generic drugs form the largest segment

• With 70 per cent of market share (in terms of revenues), generic drugs form the largest segment of the Indian pharmaceutical sector.

• India supply 20 per cent of global generic medicines market exports in terms of volume, making the country the largest provider of

generic medicines globally and expected to expand even further in coming years

• Over the Counter (OTC) medicines and patented drugsconstitute 21 per cent and 9 per cent, respectively, of total market revenues of US$ 20 billion

Pharmaceutical Industry at a glance

SWOT Analysis

Increasing investments in the sector

• The Indian pharmaceuticals market increased at a CAGR of 17.46 per cent during 2005-16 with the market increasing from

US$ 6 billion in 2005 to US$ 36.7 billion in 2016 and is expected to expand at a CAGR of 15.92 per cent to US$ 55 billion by 2020.

• By 2020, India is likely to be among the top three pharmaceutical markets by incremental growth and sixth largest market globally in absolute size.

• India’s cost of production is significantly lower than that of the US and almost half of that of Europe. It gives a competitive edge to India over others.

Competitors

Strength

1. World wide leader in Cephalosporin and Anti TB drugs

2. Considerable presence in market for drugs against Asthma, Pediatrics, Diabetes, and CNS boosts the sales

3. In the US and Japanese market it is the largest generic player

4. Acquisition of I’rom pharma helped to increase its product list and in turn sales

5. Wide global footprint as it is present in over 70 countries

Weakness

1.High dependence on global formulation business with 84% revenue coming from US market

3. Forecasting done on technological level is less

4. It operates in low growth segments such CNS, respiratory diseases

Opportunities

1.Increased health awareness

2. Emerging technological trends in drug delivery

3. Increasing prevalence of TB in developing countries

Threats

1.Unsuccessful assimilation of questions

2.Rigid opposition both from locals and global company

3. Soaring cost of discovering novel products

1. Sun pharmaceuticals

2. Ranbaxy

3. Dr. Reddy’s lab

4. Cipla

Background and Origin

Board of Directors

Market Profile

• Founded in 1968 by the Chairman, Dr. Desh Bandhu Gupta
• Now spread over 6 locations in India and a joint venture in Thailand
• Represented through Sales offices in UK, USA, Hong Kong, Japan and CIS

1. Segment -Anti TB segment, Cardiovascular, Oral and injectable, pediatric products API’s, Anti-Infectives segment.

2.Target Group-Healthcare professionals, doctors treating patients suffering from TB, respiratory & cardiovascular diseases.

3.Positioning-It is innovation led pharmaceutical company, which specializes in generic, API & branded formulations for developed & developing world.